These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31367163)

  • 1. Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis.
    Cao J; Kong FH; Liu X; Wang XB
    World J Gastroenterol; 2019 Jul; 25(27):3649-3663. PubMed ID: 31367163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: A systematic review and meta-analysis.
    Chen C; Ma YH; Zhang YT; Zhang F; Zhou N; Wang X; Liu T; Li YM
    Cytotherapy; 2018 Aug; 20(8):975-989. PubMed ID: 30072299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review.
    Cai XR; Li X; Lin JX; Wang TT; Dong M; Chen ZH; Jia CC; Hong YF; Lin Q; Wu XY
    Oncotarget; 2017 May; 8(19):31318-31328. PubMed ID: 28412743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine-induced killer cell infusion combined with conventional treatments produced better prognosis for hepatocellular carcinoma patients with barcelona clinic liver cancer B or earlier stage: A systematic review and meta-analysis.
    Li YC; Zhao L; Wu JP; Qu CX; Song QK; Wang RB
    Cytotherapy; 2016 Dec; 18(12):1525-1531. PubMed ID: 27746013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: A meta-analysis.
    He G; Zheng C; Huo H; Zhang H; Zhu Z; Li J; Zhang H
    Int Immunopharmacol; 2016 Nov; 40():436-442. PubMed ID: 27716591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic Cell Immunotherapy Combined with Cytokine-Induced Killer Cells Effectively Suppresses Established Hepatocellular Carcinomas in Mice.
    Jung NC; Lee JH; Choi HJ; Hwang SU; Song JY; Seo HG; Choi J; Jung SY; Han SG; Lim DS
    Immunol Invest; 2016 Aug; 45(6):553-65. PubMed ID: 27410037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
    Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
    Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effect and safety of dendritic cell-cytokine-induced killer cell immunotherapy for pancreatic cancer: a systematic review and meta-analysis.
    Liu YL; Yang LX; Zhang F; Tang BS; Zhao LT; Zhu JR; Jin QY; Wang RX; Li YM
    Cytotherapy; 2019 Oct; 21(10):1064-1080. PubMed ID: 31462394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal perfusion of cytokine-induced killer cells with local hyperthermia for advanced hepatocellular carcinoma.
    Wang XP; Xu M; Gao HF; Zhao JF; Xu KC
    World J Gastroenterol; 2013 May; 19(19):2956-62. PubMed ID: 23704829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Efficacy and Safety of Dendritic Cells Co-Cultured with Cytokine-Induced Killer Cell Therapy in Combination with TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma: a Meta-Analysis.
    Su Y; Yang Y; Ma Y; Zhang Y; Rao W; Yang G; Kou C
    Clin Lab; 2016; 62(4):599-608. PubMed ID: 27215078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the Clinical Efficacy of Dendritic Cell -cytokine Induced Killer Cell-based Adoptive Immunotherapy for Colorectal Cancer.
    Xu H; Qin W; Feng H; Song D; Yang X; Zhang J
    Immunol Invest; 2021 Aug; 50(6):622-633. PubMed ID: 32718264
    [No Abstract]   [Full Text] [Related]  

  • 12. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up.
    Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
    Cancer Immunol Immunother; 2019 Jan; 68(1):23-32. PubMed ID: 30232520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of adoptive immunotherapy in postoperative hepatocellular carcinoma.
    Zhao H; Zheng M; Wang K; Wang L; He H; Wang M; Shi Y; Huang S; Ji F; Li X; Zhu H; Wang L; Zhang X; Shi X; Zhao S; Fu B; Wu T
    J Cancer Res Ther; 2018; 14(4):807-814. PubMed ID: 29970657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta-analysis of 29 trials involving 2,610 patients.
    Zhang L; Mu Y; Zhang A; Xie J; Chen S; Xu F; Wang W; Zhang Y; Ren S; Zhou C
    Oncotarget; 2017 Jul; 8(28):45164-45177. PubMed ID: 28404886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of DC-CIK combined with sorafenib in the treatment of advanced hepatocellular carcinoma.
    Zhou Z; Qin H; Weng L; Ni Y
    J BUON; 2019; 24(2):615-621. PubMed ID: 31128014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients.
    Pan K; Li YQ; Wang W; Xu L; Zhang YJ; Zheng HX; Zhao JJ; Qiu HJ; Weng DS; Li JJ; Wang QJ; Huang LX; He J; Chen SP; Ke ML; Wu PH; Chen MS; Li SP; Xia JC; Zeng YX
    Ann Surg Oncol; 2013 Dec; 20(13):4305-11. PubMed ID: 23892527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma.
    Pan QZ; Liu Q; Zhou YQ; Zhao JJ; Wang QJ; Li YQ; Tang Y; Gu JM; He J; Chen SP; Weng DS; Xia JC
    Cancer Immunol Immunother; 2020 May; 69(5):825-834. PubMed ID: 32060687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis.
    Yu R; Yang B; Chi X; Cai L; Liu C; Yang L; Wang X; He P; Lu X
    Drug Des Devel Ther; 2017; 11():851-864. PubMed ID: 28360510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma.
    Cui J; Wang N; Zhao H; Jin H; Wang G; Niu C; Terunuma H; He H; Li W
    Int J Cancer; 2014 Jan; 134(2):342-51. PubMed ID: 23825037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data.
    Yoon JS; Song BG; Lee JH; Lee HY; Kim SW; Chang Y; Lee YB; Cho EJ; Yu SJ; Sinn DH; Kim YJ; Lee JH; Yoon JH
    BMC Cancer; 2019 May; 19(1):523. PubMed ID: 31151419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.